ClinicalTrials.gg

Program

GSK4347859

A development code.

In GlaxoSmithKline's pipeline, Interferon pathway modulator. Its studies are mostly in Lupus Erythematosus, Systemic, led by GlaxoSmithKline.

Furthest: phase 1, since Dec 19, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 1since Dec 19, 2023Dec 19, 2023none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK4347859, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2023First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06188507 · 65 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06188507Lupus Erythematosus, Systemic · United Kingdom1SuspendedJul 14, 202665

How it is read

Names in the registry

  • “GSK4347859”, 1 entry

Codes read as this program: GSK4347859.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.